A Phase 2 clinical trial titled "ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)" was updated on August 26, 2026. The trial, registered as NCT05630612, is now listed as active but not recruiting. This study is investigating ETA and AT1 receptor antagonism in patients with ANCA-vasculitis. Bradykinin, an unapproved compound currently in the research stage, is associated with this trial listing. No results have been posted for this study as of this update. The trial status indicates that enrollment has closed but participants already enrolled continue to be followed or treated according to the study protocol. No efficacy or safety outcomes have been disclosed as part of this status update. Readers should note that this brief reflects only the trial phase, status, and title as registered, without additional interpretation of results or clinical implications. For more background on bradykinin, including its research context and regulatory status, readers can consult the compound overview.
Trial Update: Phase 2 SPARVASC Study Now Active, Not Recruiting
See the full bradykinin overview
Source: https://clinicaltrials.gov/study/NCT05630612